OCUL — Ocular Therapeutix Income Statement
0.000.00%
Last trade - 00:00- $1.98bn
- $1.31bn
- $51.95m
- 63
- 13
- 28
- 25
Annual income statement for Ocular Therapeutix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 43.5 | 51.5 | 58.4 | 63.7 | 52 |
| Cost of Revenue | |||||
| Gross Profit | 39.1 | 47 | 53.2 | 58.1 | 45.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 122 | 130 | 127 | 263 | 322 |
| Operating Profit | -78 | -78.7 | -68.2 | -200 | -270 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.55 | -71 | -80.7 | -194 | -266 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.55 | -71 | -80.7 | -194 | -266 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.55 | -71 | -80.7 | -194 | -266 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.55 | -71 | -80.7 | -194 | -266 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.086 | -0.924 | -1.19 | -1.05 | -1.42 |